Pan-cancer multi-omics interrogation of BRI3BP across 28 malignancies spanning epithelial, mesenchymal, and hematopoietic lineages (TCGA PanCancer Atlas) revealed its oncogenic overexpression as a hallmark of aggressive disease biology, including HCC, cholangiocarcinoma (CHOL), kidney renal clear cell carcinoma (KIRC) and lung squamous cell carcinoma (LUSC) (Fig. 1a). Here, BRI3BP is linked to cholangiocarcinoma.